| Literature DB >> 28292273 |
Mebrahtu Teweldemedhin1,2, Muthupandian Saravanan3, Araya Gebreyesus1, Dawit Gebreegziabiher1.
Abstract
BACKGROUND: External and intraocular infections can lead to visual impairments, which is a major public health problem. Bacteria are the most frequent pathogens affecting ocular structures; the increasing rate of antimicrobial drug resistance is a worldwide concern. The aim of this study was to determine the occurrence of bacteria in ocular infections, their antimicrobial susceptibility patterns, and risk factors in bacterial ocular infection.Entities:
Keywords: Antimicrobial susceptibility; Bacterial occurrence; Multidrug resistance; Ocular infection; Risk factor
Mesh:
Substances:
Year: 2017 PMID: 28292273 PMCID: PMC5351251 DOI: 10.1186/s12879-017-2304-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Sociodemographic characteristics of the study subjects (N = 270)
| Characteristic | Number | Percentage (%) |
|---|---|---|
| Gender | ||
| Male | 119 | 44.1 |
| Female | 151 | 55.9 |
| Age (years) (mean (SD) = 37.8 22.9) | ||
| Less than 16 | ||
| 16–30 | 58 | 21.5 |
| 31–45 | 49 | 18.1 |
| 46–60 | 64 | 23.7 |
| Greater than 60 | 51 | 18.9 |
| 48 | 17.8 | |
| Residence | ||
| Rural | 158 | 58.5 |
| Urban | 112 | 41.5 |
| Occupation | ||
| Preschool | 30 | 11.1 |
| Student | 40 | 14.8 |
| Housewife | 43 | 15.9 |
| Farmer | 91 | 33.7 |
| Governmental employee | 34 | 12.6 |
| Self-employed | 32 | 11.9 |
| Total | 270 | 100 |
| Educational level | ||
| Preschool | 30 | 11.1 |
| 1–8 grades | 66 | 24.1 |
| 9–12 grades | 34 | 12.6 |
| College and above | 18 | 6.7 |
| No formal education | 122 | 45.2 |
| Total | 270 | 100 |
The distribution of culture positive samples in ocular infection
| Clinical diagnosis | Bacterial Culture positive | Total, | |
|---|---|---|---|
| No (%) | Yes (%) | ||
| Periorbital cellulitis | 1 (12.5) | 7 (87.5) | 8 (100) |
| Dacryocystitis | 1 (7.7) | 12 (92.3) | 13 (100) |
| Blepharitis | 12 (46.2) | 14 (53.8) | 26 (100) |
| Blepharoconjunctivitis | 10 (62.5) | 6 (37.5) | 16 (100) |
| Conjunctivitis | 48 (39) | 75 (61) | 123 (100) |
| Keratitis | 11 (19.3) | 46 (80.7) | 57 (100) |
| Endophthalmitis | 7 (25.9) | 20 (74.1) | 27 (100) |
The distribution of bacteria according to clinical diagnosis
| Type of bacterial isolate, | Clinical diagnosis | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| P’orbital cellulitisa | Dacryocystitis | Blepharitis | Blepharoconjunctivitis | Conjunctivitisb | Keratitisc | Endophthalmitisd | ||
|
| 4 (50) | 3 (25) | 5 (38.5) | 2 (33.3) | 17 (21.5) | 7 (14.9) | 2 (9.5) | 40 (21.5) |
| CoNSe | 0 | 0 | 3 (23.1) | 1 (16.7) | 13 (16.5) | 8 (17) | 6 (28.6) | 31 (16.7) |
|
| 1 (12.5) | 3 (25) | 0 | 0 | 1 (1.3) | 0 | 0 | 5 (2.7) |
|
| 2 (25) | 2 (16.7) | 0 | 1 (16.7) | 3 (3.8) | 0 | 0 | 8 (4.3) |
| Viridans streptococci | 0 | 0 | 0 | 0 | 6 (7.6) | 1 (2.1) | 0 | 7 (3.8) |
|
| 0 | 0 | 0 | 0 | 6 (7.6) | 2 (4.3) | 0 | 8 (4.3) |
|
| 1 (12.5) | 0 | 0 | 0 | 0 | 1 (2.1) | 0 | 2 (1.1) |
|
| 0 | 0 | 0 | 0 | 1 (1.3) | 0 | 0 | 1 (0.5) |
|
| 0 | 0 | 0 | 0 | 2 (2.5) | 0 | 0 | 2 (1.1) |
|
| 0 | 0 | 1 (7.7) | 0 | 2 (2.5) | 11 (23.4) | 7 (33.3) | 21 (11.3) |
|
| 0 | 1 (8.3) | 1 (7.7) | 0 | 2 (2.5) | 1 (2.1) | 2 (9.5) | 7 (3.8) |
|
| 0 | 1 (8.3) | 0 | 0 | 2 (2.5) | 2 (4.3) | 0 | 5 (2.7) |
|
| 0 | 1 (8.3) | 1 (7.7) | 1 (16.7) | 7 (8.9) | 4 (8.5) | 1 (4.8) | 15 (8.1) |
|
| 0 | 1 (8.3) | 1 (7.7) | 0 | 5 (6.3) | 3 (6.4) | 0 | 10 (5.4) |
|
| 0 | 0 | 0 | 0 | 2 (2.5) | 2 (4.3) | 0 | 4 (2.2) |
|
| 0 | 0 | 0 | 1 (16.7) | 3 (3.8) | 1 (2.1) | 0 | 5 (2.7) |
|
| 0 | 0 | 0 | 0 | 1 (1.3) | 1 (2.1) | 0 | 2 (1.1) |
|
| 0 | 0 | 0 | 0 | 1 (1.3) | 0 | 0 | 1 (0.5) |
|
| 0 | 0 | 0 | 0 | 2 (2.5) | 1 (2.1) | 0 | 3 (1.6) |
|
| 0 | 0 | 1 (7.7) | 0 | 1 (1.3) | 2 (4.3) | 1 (4.8) | 5 (2.7) |
| GPBf | 0 | 0 | 0 | 0 | 2 (2.5) | 0 | 2 (9.5) | 4 (2.2) |
| Total | 8 (100) | 12 (100) | 13 (100) | 6 (100) | 79 (100) | 47 (100) | 21 (100) | 186 (100) |
Notes: amixed isolate in one case: S. pneumoniae + H. influenzae; bmixed isolates in three cases: E. coli + P. aeruginosa; E. coli + S. aureus & S. marcescens + S. aureus ; cmixed isolate in one case: P. aeruginosa + S. aureus ; dmixed isolate in one case: E. coli + CoNS; e CoNS Coagulase negative staphylococci; f GPB Gram-positive bacilli, P’orbital cellulitis = Periorbital cellulitis
Multivariate logistic regression analysis of factors associated with ocular bacterial infections
| Variable | Bacterial occurrence, N (%) | Total, | CORa (95% CIb), | AORc (95% CI), | |
|---|---|---|---|---|---|
| No | Yes | ||||
| History of ocular surface disease | |||||
| Yes | 10 (11.0) | 81 (89.0) | 91 (100) | 6.5 (3.2–13.4), <0.01 | 13.6 (3.8–49), <0.01 |
| No | 80 (44.7) | 99 (53.3) | 179 (100) | 1 | 1 |
| History of ocular trauma | |||||
| Yes | 14 (16.7) | 70 (83.3) | 84 (100) | 3.4 (1.8–6.5), <0.01 | 4.2 (1.4–13), 0.012 |
| No | 76 (40.9) | 110 (59.1) | 186 (100) | 1 | 1 |
| History of hospitalization | |||||
| Yes | 9 (13.4) | 58 (86.6) | 67 (100) | 4.3 (2–9), <0.01 | 3.3 (1.03–12.5), 0.04 |
| No | 81 (39.9) | 122 (60.1) | 203 (100) | 1 | 1 |
| Cosmetic application practices | |||||
| Yes | 7 (12.1) | 51 (87.9) | 58 (100) | 5.3 (2.2–12.8), <0.01 | 4.7 (1.6–13.9), <0.01 |
| No | 39 (41.9) | 54 (58.1) | 93 (100) | 1 | 1 |
Notes: COR Crude odds ratio; b CI Confidence interval; c AOR Adjusted odds ratio
Bivariate logistic regression analysis of factors associated with ocular bacterial infections
| Variable | Bacterial occurrence | Total | CORa | 95% CIb |
| |
|---|---|---|---|---|---|---|
| No | Yes | |||||
| Gender | ||||||
| Male | 41 (34.5) | 78 (65.5) | 119 (100) | 0.9 | 0.5–1.5 | 0.7 |
| Female | 49 (32.5) | 102 (67.5) | 151 (100) | 1 | ||
| Age | ||||||
| 15 | 28 (48.3) | 30 (51.7) | 58 (100) | 1 | ||
| 16–30 | 15 (30.6) | 34 (69.4) | 49 (100) | 2.1 | 0.9–4.6 | 0.06 |
| 31–45 | 17 (26.6) | 47 (73.4) | 64 (100) | 2.6 | 1.2–5.5 | 0.01 |
| 46–60 | 14 (27.5) | 37 (72.5) | 51 (100) | 2.5 | 1.1–5.5 | 0.02 |
| 61 | 16 (33.3) | 32 (66.7) | 48 (100) | 1.8 | 0.8–4.1 | 0.1 |
| Residence | ||||||
| Rural | 48 (30.4) | 110 (69.6) | 158 (100) | 0.7 | 0.4–1.2 | 0.22 |
| Urban | 42 (37.5) | 70 (39.1) | 112 (100) | 1 | ||
| Occupation | ||||||
| Preschool | 13 (43.3) | 17 (56.7) | 30 (100) | 1.0 | 0.4–2.7 | 0.8 |
| Student | 18 (45.0) | 22 (55.0) | 40 (100) | 1 | ||
| Housewife | 11 (25.6) | 32 (74.4) | 43 (100) | 2.3 | 0.9–6.0 | 0.06 |
| Farmer | 25 (27.5) | 66 (72.5) | 91 (100) | 2.1 | 0.9–4.6 | 0.051 |
| Government employee | 13 (38.2) | 21 (61.8) | 34 (100) | 1.3 | 0.5–3.3 | 0.2 |
| Self-employed | 10 (31.3) | 22 (68.8) | 32 (100) | 1.8 | 0.6–4.7 | 0.2 |
| Educational level | ||||||
| Preschool | 13 (43.3) | 17 (56.7) | 30 (100) | 0.8 | 0.25–2.7 | 0.7 |
| 1–8 | 28 (42.4) | 38 (57.6) | 66 (100) | 0.9 | 0.3–2.5 | 0.8 |
| 9–12 | 10 (29.4) | 24 (70.6) | 34 (100) | 1.5 | 0.7–4.2 | 0.2 |
| College and above | 7 (38.9) | 11 (61.1) | 18 (100) | 1 | ||
| No formal education | 32 (26.2) | 90 (73.8) | 122 (100) | 1.8 | 0.6–5.0 | 0.2 |
| History of ocular surface disease | ||||||
| Yes | 10 (11.0) | 81 (89.0) | 91 (100) | 6.5 | 3.2–13.4 |
|
| No | 80 (44.7) | 99 (53.3) | 179 (100) | 1 | ||
| History of Ocular surgery | ||||||
| Yes | 14 (24.6) | 43 (75.4) | 57 (100) | 1.7 | 0.8–3.3 | 0.11 |
| No | 76 (35.7) | 137 (64.3) | 213 (100) | 1 | ||
| History of Ocular trauma | ||||||
| Yes | 14 (16.7) | 70 (83.3) | 84 (100) | 3.4 | 1.8–6.5 |
|
| No | 76 (40.9) | 110 (59.1) | 186 (100) | 1 | ||
| History of Hospitalization | ||||||
| Yes | 9 (13.4) | 58 (86.6) | 67 (100) | 4.3 | 2–9 |
|
| No | 81 (39.9) | 122 (60.1) | 203 (100) | 1 | ||
| Contact lens use | ||||||
| Yes | 4 (30.8) | 9 (69.2) | 13 (100) | 1.1 | 0.3–3.7 | 0.8 |
| No | 86 (33.5) | 171 (66.5) | 257 (100) | 1 | ||
| Cosmetic application practices | ||||||
| Yes | 7 (12.1) | 51 (87.9) | 58 (100) | 5.3 | 2.2–12.8 |
|
| No | 39 (41.9) | 54 (58.1) | 93 (100) | 1 | ||
Notes: a COR Crude odds ratio; b CI Confidence interval; P-values in bold are statistically significant
Antimicrobial susceptibility of bacteria isolated from ocular infections
| Bacterial isolate (N) | S/R | Antibiotics tested | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CN | AK | C | CIP | TC | DOX | SXT | CRO | DA | E | CH | MET | ||
|
| R | 5 (12.5) | 1 (2.5) | 11 (27.5) | 5 (12.5) | 18 (45) | 11 (27.5) | 17 (42.5) | NT | 9 (22.5) | 8 (20) | NT | 7 (17.5) |
| CoNSa (31) | R | 2 (6.5) | 1 (3.2) | 9 (29) | 3 (9.7) | 18 (58.1) | 7 (22.6) | 21 (67.7) | NT | 12 (38.7) | 9 (29) | NT | 14 (45.2) |
|
| R | NT | NT | 2 (40) | NT | 1 (20) | NT | NT | NT | 0 | 0 | 0 | NT |
|
| R | NT | NT | 2 (25) | NT | 4 (50) | 2 (25) | 3 (37.5) | NT | 1 (12.5) | 1 (12.5) | 0 | NT |
| Viridans streptococci (7) | R | NT | NT | 3 (42.9) | NT | 2 (28.6) | NT | NT | 0 | NT | 1 (14.3) | 0 | NT |
|
| R | NT | NT | 4 (50) | 1 (12.5) | 4 (50) | 2 (25) | NT | NT | NT | 1 (12.5) | NT | NT |
|
| R | NT | NT | NT | 0 | 0 | NT | NT | 0 | NT | NT | NT | NT |
|
| R | NT | NT | 0 | 0 | 0 | NT | 1 (50) | NT | NT | NT | 0 | NT |
|
| R | 1 (4.8) | 1 (4.8) | NT | 4 (19) | NT | NT | NT | NT | NT | NT | NT | NT |
|
| R | 2 (28.6) | 1 (14.3) | 3 (42.9) | 1 (14.3) | 5 (71.4) | 2 (28.6) | 4 (57.1) | 3 (42.9) | NT | NT | NT | NT |
| Other | R | 0 | 1 (20) | 2 (40) | 1 (20) | 2 (40) | 1 (20) | 4 (80) | 0 | NT | NT | NT | NT |
|
| R | 3 (20) | 2 (13.3) | 4 (26.7) | 1 (6.7) | 8 (53.3) | 3 (20) | 8 (53.3) | 3 (20) | NT | NT | NT | NT |
|
| R | 1 (10) | 1 (10) | 1 (10) | 0 | 6 (60) | 5 (50) | 4 (40) | 2 (20) | NT | NT | NT | NT |
|
| R | 0 | 0 | 2 (50) | 1 (25) | 3 (75) | 2 (50) | 1 (25) | 0 | NT | NT | NT | NT |
|
| R | 1 (20) | 1 (20) | NT | 0 | 3 (60) | 3 (60) | 4 (80) | 0 | NT | NT | NT | NT |
|
| R | 1 (20) | 1 (20) | 2 (40) | 0 | 1 (20) | 1 (20) | 2 (40) | 1 (20) | NT | NT | NT | NT |
|
| R | 0 | 0 | 0 | 0 | NT | NT | 1 (33.3) | 0 | NT | NT | NT | NT |
|
| R | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NT | NT | NT | NT |
| Total, N (%) | R | 16 (10.9) | 10 (6.8) | 45 (29.8) | 17 (10.8) | 75 (48.7) | 39 (28.1) | 70 (51.3) | 9 (14.3) | 22 (26.2) | 20 (20.2) | 0 | 21 (29.6) |
Notes: S Susceptible, R Resistant, CN Gentamicin, AK Amikacin, C Chloramphenicol, CIP Ciprofloxacin, TC Tetracycline, DOX Doxycycline, SXT Trimethoprim-sulfamethoxazole, CRO Ceftriaxone, DA Clindamycin, E Erythromycin, CH Clarithromycin, MET Methicillin, NT Not tested; a CoNS Coagulase negative staphylococci
Level of antimicrobial resistance in bacteria isolated from ocular infections
| Type of bacterial isolate | Level of resistance | Total | |||||
|---|---|---|---|---|---|---|---|
| R0 | R1 | R2 | R3 | R4 | |||
| Gram-positive |
| 7 (17.5) | 8 (20) | 6 (15) | 7 (17.5) | 12 (30) | 40 (100) |
| CoNSa | 4 (12.9) | 6 (19.4) | 5 (16.1) | 0 | 16 (51.6) | 31 (100) | |
|
| 3 (60) | 2 (40) | 0 | 0 | 0 | 5 (100) | |
|
| 1 (12.5) | 2 (25) | 4 (50) | 0 | 1 (12.5) | 8 (100) | |
| Viridans streptococci | 2 (28.6) | 2 (28.6) | 2 (28.6) | 1 (14.3) | 0 | 7 (100) | |
|
| 2 (25) | 1 (12.5) | 4 (50) | 1 (12.5) | 0 | 8 (100) | |
| Total | 19 (19.2) | 21 (21.2) | 21 (21.2) | 9 (9) | 29 (29.3) | 99 (100) | |
| Gram-negative |
| 1 (100) | 0 | 0 | 0 | 0 | 1 (100) |
|
| 1 (50) | 1 (50) | 0 | 0 | 0 | 2 (100) | |
|
| 10 (47.6) | 9 (42.9) | 2 (9.5) | 0 | 0 | 21 (100) | |
|
| 0 | 0 | 1 (14.3) | 5 (71.4) | 1 (14.3) | 7 (100) | |
| Other | 0 | 2 (40) | 1 (20) | 1 (20) | 1 (20) | 5 (100) | |
|
| 5 (33.3) | 2 (13.3) | 1 (6.7) | 1 (6.7) | 6 (40) | 15 (100) | |
|
| 2 (20) | 2 (20) | 3 (30) | 1 (10) | 2 (20) | 10 (100) | |
|
| 1 (25) | 0 | 1 (25) | 1 (25) | 1 (25) | 4 (100) | |
|
| 2 (40) | 1 (20) | 0 | 1 (20) | 1 (20) | 5 (100) | |
|
| 1 (100) | 0 | 0 | 0 | 0 | 1 (100) | |
|
| 0 | 0 | 2 (66.7) | 1 (33.3) | 0 | 3 (100) | |
|
| 0 | 2 (40) | 1 (20) | 1 (20) | 1 (20) | 5 (100) | |
| Total | 23 (29.1) | 19 (24) | 13 (16.5) | 11 (13.9) | 13 (16.5) | 79 (100) | |
| Grand Total | 42 (23.6) | 40 (22.5) | 34 (19.1) | 20 (11) | 42 (23.5) | 178 (100) | |
Notes: R0 Susceptible to all tested antimicrobials, R1 Resistant to one antimicrobial, R2 Resistant to two antimicrobials, R3 Resistant to three antimicrobials, R4 Resistant to four or more antimicrobials; a CoNS Coagulase negative staphylococci
Multidrug resistance patterns of bacterial isolates from ocular infections
| Type of bacterial isolate | Total number of isolates | MDRa isolates, |
|---|---|---|
|
| 40 | 18 (45) |
|
| 7 | 4 (57.1) |
| Other | 5 | 2 (40) |
|
| 15 | 7 (46.7) |
|
| 10 | 2 (20) |
|
| 4 | 1 (25) |
|
| 5 | 1 (20) |
|
| 1 | 0 |
|
| 3 | 0 |
|
| 5 | 1 (20) |
| Total | 95 | 36 (37.9) |
Notes: a MDR Multi-drug resistant: non-susceptible to 1 agent in 3 antimicrobial categories [43]. Based on this definition, the following antimicrobial categories were considered to determine whether the given isolate is MDR: S. aureus: aminoglycosides, methicillin, SXT, clindamycin, chloramphenicol, macrolides (erythromycin), tetracyclines and fluoroquinolones (ciprofloxacin). Enterobacteriaceae: aminoglycosides, ceftriaxone, fluoroquinolones (ciprofloxacin), SXT, chloramphenicol and tetracyclines. Acinetobacter spp.: aminoglycosides, fluoroquinolones (ciprofloxacin), ceftriaxone, SXT and tetracyclines